To assess patient satisfaction with respect to the incidence of flu-like symptoms (FLS) in
patients with multiple sclerosis transitioned from current Rebif (subcutaneously injected
interferon beta-1a, 44 mcg three-times-weekly) to the new formulation of Rebif (RNF) while
receiving ibuprofen either prophylactically or only when necessary (PRN) after the occurence
of flu-like symptoms.